Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of “Buy” by Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has received an average recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $18.08.

Several research firms have recently commented on ROIV. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th.

Insider Buying and Selling

In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. This represents a 58.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $11.49, for a total transaction of $1,149,000.00. Following the sale, the chief operating officer now owns 595,580 shares of the company’s stock, valued at $6,843,214.20. This trade represents a 14.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,288,170 shares of company stock worth $26,547,299. Corporate insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds have recently bought and sold shares of the company. FMR LLC boosted its holdings in Roivant Sciences by 0.3% during the fourth quarter. FMR LLC now owns 49,301,583 shares of the company’s stock valued at $583,238,000 after acquiring an additional 156,527 shares during the period. Vanguard Group Inc. boosted its holdings in Roivant Sciences by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after acquiring an additional 2,404,232 shares during the period. State Street Corp boosted its holdings in Roivant Sciences by 6.1% during the third quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after acquiring an additional 1,118,561 shares during the period. Patient Square Capital LP boosted its holdings in Roivant Sciences by 2.1% during the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company’s stock valued at $147,638,000 after acquiring an additional 251,535 shares during the period. Finally, Two Seas Capital LP boosted its holdings in Roivant Sciences by 4.6% during the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company’s stock valued at $120,285,000 after acquiring an additional 442,914 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Stock Down 0.4 %

Roivant Sciences stock opened at $10.68 on Friday. The company’s fifty day simple moving average is $11.21 and its 200-day simple moving average is $11.58. Roivant Sciences has a 12 month low of $9.76 and a 12 month high of $13.06. The stock has a market cap of $7.62 billion, a P/E ratio of -71.20 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities research analysts expect that Roivant Sciences will post -0.92 earnings per share for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.